Overview

A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer

Status:
Recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

This clinical trial is aimed to establish a recommended starting dose of ipilimumab for a future efficacy trial when used in combination with intensity modulated radiation therapy (IMRT) and cetuximab.

Phase:

Phase 1

Details

Lead Sponsor:

University of Pittsburgh

Collaborator:

National Cancer Institute (NCI)

Treatments:

Antibodies, Monoclonal
Cetuximab